Vertex Pharmaceuticals Incorporated(VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest News & Analysis
Vertex's Kidney Disease Validation: The Clinical Proof Behind Diversification
RUBY-3 Phase 1/2 data validates povetacicept in kidney disease, de-risking Vertex's diversification strategy and potential $1.5-2.0 billion revenue opportunity.
Vertex Pharmaceuticals Faces Payment Model Challenges for Gene Therapies
An in-depth update on Vertex's gene therapy payment models, pipeline diversification, and trial investigation issues.
Vertex Pharmaceuticals: Pipeline Expansion and Market Impact
An in-depth analysis of Vertex’s pipeline diversification, market dynamics, and recent developments impacting its strategic outlook.
Vertex Pharmaceuticals: Investor Conference, Gene Therapy Challenges
Vertex Pharmaceuticals is navigating growth opportunities and challenges in 2025, including investor conferences and clinical trials. This analysis provides a comprehensive overview.
Vertex Pharmaceuticals (VRTX): Investor Conference Preview, JOURNAVX Launch, and Pipeline Update
Vertex Pharmaceuticals navigates investor expectations, JOURNAVX launch, and pipeline updates amid evolving healthcare landscape. A comprehensive analysis follows.
Vertex Pharmaceuticals (VRTX): Navigating Growth and Challenges in 2025
Vertex Pharmaceuticals (VRTX) navigates growth and challenges in 2025 amid investor interest, reimbursement hurdles, and clinical trial outcomes. A detailed analysis follows.
Vertex Pharmaceuticals: Growth, Gene Therapy, and Pipeline Updates
Vertex Pharmaceuticals navigates growth opportunities and reimbursement challenges with KAFTRIO expansion, gene therapy advancements, and pipeline diversification.
Vertex Pharmaceuticals: Growth, Innovation, and Strategic Developments in 2025
Vertex Pharmaceuticals reports steady stock gains, robust R&D investments, and strategic pipeline updates amid evolving market dynamics.
Vertex Pharmaceuticals (VRTX): Growth, Diversification, and Market Impact
Vertex Pharmaceuticals (VRTX) is navigating growth and diversification, driven by CF dominance and expansion into new areas. Recent approvals boost revenue, while new products offer diversification.
Vertex Pharmaceuticals (VRTX): Growth, Innovation, and Market Dominance
A comprehensive financial analysis of Vertex Pharmaceuticals (VRTX), examining its market leadership in cystic fibrosis, new drug launches, financial health, and R&D investments.
Vertex Pharmaceuticals (VRTX): Financial Analysis and Market Impact
Analysis of Vertex Pharmaceuticals (VRTX): Recent Alyftrek® approval, financial performance, pipeline progress with VX-548 and CTX001, and competitive landscape.
Vertex Pharmaceuticals: Type 1 Diabetes Strategy, Financial Analysis
Vertex Pharmaceuticals focuses on Type 1 Diabetes with zimislecel, while discontinuing VX-264. Revenue grows, but net income declines. Tariff threats loom, yet CF dominance offers resilience.
Vertex (VRTX): Kaftrio Expansion, Journavx Launch, and Q1 Outlook
Vertex Pharmaceuticals navigates growth with Kaftrio expansion and Journavx launch. Q1 2025 earnings are keenly watched for insights into performance and prospects.
Vertex Pharmaceuticals (VRTX): Analyzing 2024 Financials and 2025 Pipeline
Vertex Pharmaceuticals saw revenue growth in 2024, but profitability metrics shifted significantly. We analyze Q1 2025 results, pipeline progress, and strategic implications.
Vertex Pharmaceuticals: T1D Pipeline Drives Strategic Financial Shift
Vertex Pharmaceuticals' 2024 financials reveal a strategic pivot, with a significant net loss of -$535.6 million, driven by aggressive R&D in Type 1 Diabetes.
Vertex Pharmaceuticals' T1D Pivot: Financial Impact & Clinical Data
Vertex's strategic pivot into Type 1 Diabetes faces scrutiny as 2024 financials show a significant net loss amidst soaring R&D costs.
Vertex Pharmaceuticals Latest Analysis: T1D Pipeline Advances and Financial Resilience
Explore Vertex Pharmaceuticals' strategic pivot to Type 1 Diabetes with VX-880, Ono partnership, and key financial trends shaping its future.
Vertex Pharmaceuticals' EU Approval of ALYFTREK Boosts CF Market Leadership and Financial Outlook
Vertex Pharmaceuticals secures EU approval for ALYFTREK, expanding its cystic fibrosis market and impacting financials with strategic growth and R&D investment.
Vertex Pharmaceuticals Q2 2025 Update: Alyftrek EU Approval and Pipeline Momentum Drive Strategic Growth
Vertex Pharmaceuticals gains momentum from Alyftrek EU approval and pipeline advances, impacting Q2 2025 earnings and strengthening future revenue prospects.
Vertex Pharmaceuticals Expands with FDA-Approved JOURNAVX™ in $70B Non-Opioid Pain Market | Monexa AI Analysis
Vertex Pharmaceuticals pivots beyond cystic fibrosis with FDA approval of JOURNAVX™, targeting the $70B non-opioid pain market. Explore financial impact and market dynamics.
Vertex Pharmaceuticals NHS Reimbursement Deal and Strategic Diversification Boost
Vertex Pharmaceuticals secures NHS England reimbursement for ALYFTREK®, enhancing UK cystic fibrosis market access and advancing pipeline diversification.
Vertex Pharmaceuticals: Regulatory Wins and Pipeline Drives 2025
Vertex Pharmaceuticals sees key regulatory wins for ALYFTREK and significant pipeline progress in 2025, driving market interest and investor focus.
Vertex Pharmaceuticals (VRTX) Expands Beyond Cystic Fibrosis with Diversification and R&D Focus
Vertex Pharmaceuticals broadens its portfolio beyond cystic fibrosis with ALYFTREK® EU approval, new pain management drug JOURNAVX™, and strong R&D investment.
Vertex Pharmaceuticals Q2 2025: Strong CF Growth Amid Pain Drug Setback
Vertex Pharmaceuticals posts robust Q2 2025 CF revenue of $2.96B despite VX-993 pain drug failure, highlighting strategic pipeline shifts and market reactions.
Vertex Pharmaceuticals: CF Revenue Strength Amid Pain-Pipeline Setbacks
Vertex shares rose as CF sales held up while VX‑993 was discontinued and Journavx faced label limits; 2024 cash drawdown and R&D intensity reshape near-term optionality.
Vertex Pharmaceuticals Q2 2025 Update: Strategic Diversification and Pipeline Catalysts Drive Growth
Vertex Pharmaceuticals shows strategic pivot with diversification and promising pipeline assets ahead of Q2 2025 earnings, supported by robust financials and innovation.
Vertex Pharmaceuticals (VRTX): Revenue Up but 2024 Cash Burn and R&D Push Raise Strategic Trade-Offs
Vertex grew revenue to $11.02B in FY2024 but swung to a -$535.6M net loss and burned $5.8B of cash, sharpening focus on pipeline execution, buybacks and capital allocation.
Vertex Pharmaceuticals (VRTX): Financial Shift and Pipeline Focus
Explore Vertex Pharmaceuticals' strategic shifts, financial health amid rising R&D, and pipeline progress in 2025, backed by recent data.
Vertex Pharmaceuticals: Cash, Pipeline and Profitability Under Test
Vertex (VRTX) posted **FY2024 revenue of $11.02B** but swung to an operating loss and burned cash — testing its strategy to convert CF cash into new franchises.
Vertex Pharmaceuticals (VRTX): Financial Pivot, Pipeline Diversification, and the Cost of Growth
Vertex posted **$11.02B** revenue in FY2024 but swung to a **-$535.6M** net loss as cash reserves fell; the company is funding multi‑franchise growth while CF still drives margins.
Vertex Pharmaceuticals: FY2024 Loss, Cash Drawdown and Pipeline Stakes
Vertex reported a **FY2024 revenue** of **$11.02B** but swung to a **net loss of $535.6M**, draining cash by **$5.8B** as the company funds near‑term launches and cell/gene scale‑up.